Model informed dosing of hydroxycholoroquine in COVID‐19 patients: Learnings from the recent experience, remaining uncertainties and gaps. Issue 2 (19th July 2020)

• Record Type: Journal Article
• Authors: Thémans, Pauline; Dauby, Nicolas; Schrooyen, Loïc; Lebout, Faustine; Delforge, Marc; Nasreddine, Rakan; Libois, Agnès; Payen, Marie‐Christine; Konopnicki, Déborah; Wuillaume, Francoise; Lescrainier, Cecile; Verlinden, Veerle; Dogné, Jean‐Michel; Hamdani, Jamila; Musuamba, Flora T.
• Is Part Of: British journal of clinical pharmacology. Volume 87:Issue 2(2021)
• Page Start: 674
• Page End: 682
• Publication Date: 2020-07-19
• Subjects: dosing optimization -- dosing rationale -- hydroxychloroquine -- modelling and simulations -- pharmacokinetics; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14436
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID‐19 disease currently vary across national guidelines and clinical study protocols. We have used a model‐based approach to explore the relative impact of alternative dosing regimens proposed in different dosing protocols for hydroxychloroquine in COVID‐19. Methods: We compared different PK exposures using Monte Carlo simulations based on a previously published population pharmacokinetic model in patients with rheumatoid arthritis, externally validated using both independent data in lupus erythematous patients and recent data in French COVID‐19 patients. Clinical efficacy and safety information from COVID‐19 patients treated with HCQ were used to contextualize and assess the actual clinical value of the model predictions. Results: Literature and observed clinical data confirm the variability in clinical responses in COVID‐19 when treated with the same fixed doses. Confounding factors were identified that should be taken into account for dose recommendation. For 80% of patients, doses higher than 800 mg day on day 1 followed by 600 mg daily on following days might not be needed for being cured. Limited adverse drug reactions have been reported so far for this dosing regimen, most often confounded by co‐medications, comorbidities or underlying COVID‐19 disease effects. Conclusion: Our results were clear, indicating the unmet need for characterization of target PK exposures to inform HCQ dosing optimization in COVID‐19. Dosing optimization for HCQ in COVID‐19 is still an unmet need. Efforts in this sense are a prerequisite for best benefit/risk balance.